BMS 'surprise' at ASCO PD-1 data spin
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's head of oncology and immunology feels his company left the annual American Society of Clinical Oncology (ASCO) meeting slightly misunderstood. In the year when "the role of immune-oncology at the entire conference was dramatically increased," according to Michael Giordano, he was "honestly surprised" that more wasn't made of some of the company's data on its programmed cell death-1 (PD-1) inhibitor nivolumab.